ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
Promotion
Recombinantタンパク質s ClearClear history
Recombinantタンパク質s CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |Omicron specific antibody Hot |Claudin 18.2 |Cadherin-17
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > PD-1

PD-1

概要

Name:Programmed cell death protein 1
Target Synonym:Programmed cell death protein 1,CD279,hPD-1,PDCD1,Programmed Cell Death 1,Systemic Lupus Erythematosus Susceptibility 2,Protein PD-1,PD1,Programmed Cell Death 1 Protein,CD279 Antigen,HPD-L,HSLE1,SLEB2,PD-1,Programmed Cell Death 1 Receptor
Number of Launched Drugs:16
Number of Drugs in Clinical Trials:150
Lastest Research Phase:Approved

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
PD-1 VHH mAb - 01 PCC Solid Tumor Solid tumor

ライセンス

Project Name Modality Therapeutic Area Indications Stage Right Available
SIRPα×PD-1 bsAb Bispecific antibody Oncology/Cancer Advanced solid tumor Preclinical Global
PD-1×TIGIT BsAb for Advanced solid tumor Bispecific antibody Oncology/Cancer Cancer Preclinical Global
SN-38 Polymeric Nanoparticle (new formulation) Small molecule Oncology/Cancer Solid tumor,Lung cancer Phase II Global

製品リスト製品比較と製品注文

製品> フィルター結果
製品仕様別：
製品カテゴリー別：
種類別：
タグ別：
コンジュゲート：
製造番号 種類 製品説明 構造 純度 特徴
CHEK-ATP143 Human HEK293/Human PD-1 Stable Cell Line
PD1-M82E3 Mouse Biotinylated Mouse PD-1 / PDCD1 Protein, His,Avitag™ (MALS verified)
PD1-M82E3-structure
PD1-M82E3-sds
PD1-M5257 Mouse Mouse PD-1 / PDCD1 Protein, Mouse IgG2a Fc Tag (MALS verified)
PD1-M5257-structure
PD1-M5257-sds
EP-163 Human PD-1 : PD-L1 [Biotinylated] Inhibitor Screening ELISA Kit-Pre coated plate
PD1-C82F7 Cynomolgus Biotinylated Cynomolgus PD-1 / PDCD1 Protein, Fc,Avitag™ (MALS verified)
PD1-C82F7-structure
PD1-C82F7-sds
HGS-S238 Mouse Recombinant Monoclonal Anti-PD-1 Antibody, Mouse (2F3)
PD1-H5286 Human Human PD-1 / PDCD1 Protein, Twin-Strep Tag (MALS verified)
PD1-H5286-structure
PD1-H5286-sds
EP-154 Human PD-1 : PD-L2 [Biotinylated] Inhibitor Screening ELISA Kit
SCJUR-STF064 Human Human PD-1 (Luc) Jurkat Reporter Cell Development Service
PD1-C52H5 Cynomolgus Cynomolgus PD-1 / PDCD1 Protein, His Tag (MALS verified)
PD1-C52H5-structure
PD1-C52H5-sds
RAB-P002 Human Human Anti-PD-1 Antibody IgG Titer Serologic ELISA Assay Kit
PD1-C52E5 Canine Biotinylated Canine PD-1 / PDCD1 Protein, His,Avitag™
PD1-C52E5-structure
PD1-C52E5-sds
EP-120 Human PD-1 [Biotinylated] : PD-L2 Inhibitor Screening ELISA Kit
EP-130 Human PD-1 : PD-L1 [Biotinylated] Inhibitor Screening ELISA Kit
PD1-H5256 Human Human PD-1 / PDCD1 Protein, Fc,His Tag
PD1-H5256-structure
PD1-H5256-sds
PD1-H52H2 Human Human PD-1 Protein, His Tag (Nanoparticle)
PD1-H52H2-sds
PD1-C52H9 Canine Canine PD-1 / PDCD1 Protein, His Tag (MALS verified)
PD1-C52H9-structure
PD1-C52H9-sds
PD1-H82A4 Human Biotinylated Human PD-1 / PDCD1 Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
PD1-H82A4-structure
PD1-H82A4-sds
PD1-R52H3 Rhesus macaque Rhesus macaque PD-1 / PDCD1 Protein, His Tag (MALS verified)
PD1-R52H3-structure
PD1-R52H3-sds
PD1-H52H6 Human Human PD-1 / PDCD1 Full Length Protein, His Tag
PD1-H52H6-structure
PD1-H52H6-sds
PD1-H82F4 Human Biotinylated Human PD-1 / PDCD1 Protein, Fc,Avitag™,His Tag (MALS verified)
PD1-H82F4-structure
PD1-H82F4-sds
PD1-C82E6 Cynomolgus Biotinylated Cynomolgus PD-1 / PDCD1 Protein, His,Avitag™
PD1-C82E6-structure
PD1-C82E6-sds
PD1-HP2F2 Human PE-Labeled Human PD-1 / PDCD1 Protein, Fc,His Tag (recommended for neutralizing assay)
PD1-HP2F2-structure
PD1-H5255 Human Human PD-1 / PDCD1 Protein, Mouse IgG2a Fc Tag (HPLC-verified)
PD1-H5255-structure
PD1-H5255-sds
PD1-H5255-hplc
PD1-H522a Human Human PD-1 / PDCD1 Protein, His Tag, low endotoxin (MALS verified)
PD1-H522a-structure
PD1-H522a-sds
EPC-V1 Monkey ELISA Assay Kit for Anti-PD-1 h-mAb in Monkey Serum
EPM-V1 Mouse ELISA Assay Kit for Anti-PD-1 h-mAb in Mouse Serum
PD1-H5259 Human Human PD-1 / PDCD1 Protein, Llama IgG2b Fc Tag, low endotoxin
PD1-H5259-structure
PD1-H5259-sds
EPH-V1 Human ELISA Assay Kit for Anti-PD-1 h-mAb in Human Serum
PD1-H82F1 Human Biotinylated Human PD-1 / PDCD1 Protein, Fc,Avitag™ (MALS verified)
PD1-H82F1-structure
PD1-H82F1-sds
PD1-RB5251 Rabbit Rabbit PD-1 / PDCD1 Protein, Fc Tag
PD1-RB5251-structure
PD1-RB5251-sds
PD1-R52H2 Rat Rat PD-1 / PDCD1 Protein, His Tag
PD1-R52H2-structure
PD1-R52H2-sds
PD1-H82E4 Human Biotinylated Human PD-1 / PDCD1 Protein, Avitag™,His Tag (recommended for biopanning) (MALS verified)
PD1-H82E4-structure
PD1-H82E4-sds
PD1-R52H0 Rabbit Rabbit PD-1 / PDCD1 Protein, His Tag (MALS verified)
PD1-R52H0-structure
PD1-R52H0-sds
PD1-M82F4 Mouse Biotinylated Mouse PD-1 / PDCD1 Protein, Fc,Avitag™ (MALS Verified)
PD1-M82F4-structure
PD1-M82F4-sds
PD1-R5253 Rat Rat PD-1 / PDCD1 Protein, Fc Tag
PD1-R5253-structure
PD1-R5253-sds
PD1-M5259 Mouse Mouse PD-1 / PDCD1 Protein, Fc Tag
PD1-M5259-structure
PD1-M5259-sds
PD1-H5284 Human Human PD-1 / PDCD1 Protein, Twin-Strep Tag (MALS verified)
PD1-H5284-structure
PD1-H5284-sds
PD1-M5228 Mouse Mouse PD-1 / PDCD1 Protein, His Tag
PD1-M5228-structure
PD1-M5228-sds
PD1-C5254 Cynomolgus Cynomolgus PD-1 / PDCD1 Protein, Fc Tag (MALS verified)
PD1-C5254-structure
PD1-C5254-sds
PD1-H5257 Human Human PD-1 / PDCD1 Protein, Fc Tag, low endotoxin (MALS Verified)
PD1-H5257-structure
PD1-H5257-sds
PD1-H5221 Human Human PD-1 / PDCD1 Protein, His Tag (MALS Verified)
PD1-H5221-structure
PD1-H5221-sds
ACRO Quality

生物活性データの一部

CHEK-ATP143-Cell-based assay
PD-1 FACS

Fig. FACS analysis of PD-1 on HEK293/Human PD-1 Stable Cell Line.
FACS assay shows that Human PD-L1 Protein, Mouse IgG1 Fc Tag can bind to HEK293/Human PD-1 Stable Cell Line. HEK293/Human PD-1 Stable Cell Line was red line, negative control HEK293 cells was grey line(QC tested).

Protocol
SCJUR-STF064-Cell-based assay
PD-1 FACS

Expression analysis of human PD-1 on Human PD-1 (Luc) Jurkat Reporter Cell by FACS.
Human PD-1 (Luc) Jurkat Reporter Cell or negative control cell were stained with FITC-labeled anti-human PD1 antibody.

Protocol
PD1-R52H0-SPR
Human_FcRn_Heterodimer_Protein_SPR

Rabbit PD-L1, His Tag (Cat. No. PDL-R52H6) immobilized on CM5 Chip can bind Rabbit PD-1, His Tag (Cat. No. PD1-R52H0) with an affinity constant of 3.87 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol
PD1-M5259-SPR
PD-1 SPR

Captured Mouse PD-1, Fc Tag (Cat. No. PD1-M5259) on Protein A Chip can bind Mouse PD-L1, His Tag (Cat. No. PD1-M5220) with an affinity constant of 2.16 μM as determined in SPR assay (Biacore T200) (Routinely tested).

Protocol

カスタマーレビュー

Synonym Name

PDCD1,PD1,CD279,SLEB2

Background

How a therapeutic antibody is metabolized in the body is pertinently relevant to its efficacy. Therefore, pharmacokinetics study is an important part of the drug development. PD-1 is probably the most targeted molecule in today’s pharmaceutical industry, thanking to the clinical success of Keytruda® and Opdivo®. Many investigational anti-PD-1 mAbs are being developed. There is a growing need for a standard assay that can be used to facilitate the study of their pharmacokinetics.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Serplulimab HLX-10 Approved Shanghai Henlius Biotech Inc 汉斯状, Zerpidio, Han Si Zhuang, HANSIZHUANG Mainland China Microsatellite instability-high cancer Shanghai Henlius Biopharmaceuticals Co Ltd 2022-03-22 Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Colorectal Neoplasms; Microsatellite Instability; Microsatellite instability-high cancer; Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Hepatitis B, Chronic; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Liver Neoplasms; Head and Neck Neoplasms Details
Nivolumab/Relatlimab BMS-986213; BMS-936558/BMS-986016 Approved Bristol-Myers Squibb Company OPDUALAG United States Melanoma Bristol-Myers Squibb Company 2022-03-18 Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Merkel Cell; Colorectal Neoplasms; Melanoma Details
Zimberelimab AB-122; GLS-010; WBP-3055 Approved Wuxi Biologics (Shanghai) Co Ltd, Harbin Gloria Pharmaceuticals Co Ltd 誉妥, YUTUO Mainland China Hodgkin Disease Guangzhou Gloria Biosciences Co Ltd 2021-08-25 Prostatic Neoplasms, Castration-Resistant; Adenocarcinoma; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal adenocarcinoma; Endometrial Neoplasms; Carcinoma, Pancreatic Ductal; Sarcoma, Alveolar Soft Part; Lung Neoplasms; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Colorectal Neoplasms; Breast Neoplasms; Multiple Myeloma; Urinary Bladder Neoplasms; Solid tumours; Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Hodgkin Disease; Glioblastoma; Pancreatic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Stomach Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms; Ovarian Neoplasms Details
Pucotenlimab AK-103; HX-008 Approved Taizhou Hanzhong Biomedical Co Ltd, Hanx Biopharmaceutical Co Ltd, Zhongshan Akeso Biopharma Co Ltd, Lepu Biotech Co Ltd 普佑恒 Mainland China Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer Lepu Biotech Co Ltd 2022-07-19 Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Mismatch Repair Deficient Cancer; Thyroid Carcinoma, Anaplastic; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Microsatellite instability-high cancer; Colorectal Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Gastrointestinal Neoplasms Details
Cemiplimab REGN-2810; SAR-439684 Approved Regeneron Pharmaceuticals Inc Libtayo United States Carcinoma, Squamous Cell Regeneron Pharmaceuticals Inc 2018-09-28 Lung Neoplasms; Sarcoma; Peritoneal Neoplasms; Diffuse Intrinsic Pontine Glioma; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Carcinoma, Brown-Pearce; Mouth Neoplasms; Glioma; Prostatic Neoplasms; Brain metastases; Endometrial Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Mycosis Fungoides; Melanoma; Carcinoma, Hepatocellular; Skin Neoplasms; Solid tumours; HIV Infections; Carcinoma, Bronchogenic; Carcinoma, Basal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Merkel Cell; Hemangiosarcoma; Carcinoma, Renal Cell; Ovarian Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Hodgkin Disease; Papillomavirus Infections; Colonic Neoplasms; Central Nervous System Neoplasms; Multiple Myeloma; Hepatitis B Details
Cadonilimab AK-104; AK104 Approved Zhongshan Akeso Biopharma Co Ltd 开坦尼 Mainland China Uterine Cervical Neoplasms Kangfang Pharmaceutical Co Ltd 2022-06-29 Nasopharyngeal Carcinoma; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Uterine Cervical Neoplasms; Esophageal Squamous Cell Carcinoma; DNA Repair-Deficiency Disorders; Urologic Neoplasms; Colorectal Neoplasms; Vulvar Neoplasms; Microsatellite Instability; Solid tumours; Microsatellite instability-high cancer; Triple Negative Breast Neoplasms; Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Vaginal Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma; Esophageal Neoplasms; Lymphoma, T-Cell, Peripheral Details
Prolgolimab BCD-100 Approved Biocad Forteca Russian Federation Melanoma Biocad 2020-04-01 Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Tislelizumab BGB-A317; VDT-482 Approved Beigene Ltd 百泽安, Tevimbra, TEVIMBRA Mainland China Hodgkin Disease Beigene (Shanghai) Biotechnology Co Ltd 2019-12-26 Lymphoma, Large-Cell, Anaplastic; Lymphoma, Extranodal NK-T-Cell; Sarcoma; Cholangiocarcinoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Lymphoma; Lymphoma, T-Cell; Nasopharyngeal Carcinoma; Lymphoma, T-Cell, Cutaneous; Lung Neoplasms; Metastatic breast cancer; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Uterine Cervical Neoplasms; Melanoma; Lymphoma, Large B-Cell, Diffuse; Solid tumours; Liver Neoplasms; Leukemia; Lymphoma, B-Cell, Marginal Zone; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Mismatch Repair Deficient Cancer; Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Carcinoma, Adenoid Cystic; Digestive System Neoplasms; Urinary Bladder Neoplasms; Microsatellite instability-high cancer Details
Toripalimab TAB-001; JS-001; JS 001; SO-001; JS-001sc; CHS-007 Approved Suzhou Union Biopharm Biosciences Co Ltd, Shanghai Junshi Biosciences Co Ltd 拓益, LOQTORZI, Tuoyi Mainland China Melanoma Shanghai Junshi Biosciences Co Ltd 2018-12-17 Esophageal Squamous Cell Carcinoma; Urinary Bladder Neoplasms; Neuroendocrine Tumors; Rejection of organ transplantation; Nasopharyngeal Carcinoma; Cholangiocarcinoma; Breast Neoplasms; Sarcoma; Colorectal Neoplasms; Urologic Neoplasms; Hodgkin Disease; Lymphoma; Laryngeal Neoplasms; Lung Neoplasms; Epstein-Barr Virus Infections; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Adenocarcinoma; Stomach Neoplasms; Kidney Neoplasms; Solid tumours; Colorectal Neoplasms, Hereditary Nonpolyposis; Biliary Tract Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Pain; Squamous Cell Carcinoma of Head and Neck; Head and Neck Neoplasms; Anus Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Nasopharyngeal Neoplasms; Nasopharyngeal Diseases; Hypopharyngeal Neoplasms; Neoplasms Details
Dostarlimab WBP-285; TSR-042; ANB-011; GSK-4057190 Approved Anaptysbio Inc JEMPERLI, Jemperli EU Endometrial Neoplasms Glaxosmithkline (Ireland) Ltd 2021-04-21 Breast Neoplasms; Melanoma; Neoplasms, Second Primary; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Duodenal Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Carcinoma, Neuroendocrine; Colorectal Neoplasms; Peritoneal Neoplasms; Ampullary Carcinoma; Sarcoma, Clear Cell; Ovarian Neoplasms; Sarcoma; Gestational Trophoblastic Disease; Mesothelioma; Adrenocortical Carcinoma; Colonic Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Neoplasms; Rectal Neoplasms; Mismatch Repair Deficient Cancer; Stomach Neoplasms; Head and Neck Neoplasms; Solid tumours Details
Camrelizumab SHR-1210; INCSHR-1210; HR-301210; SHR01210 Approved Jiangsu Hengrui Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd 艾立妥, 艾瑞卡, AiRuiKa Mainland China Hodgkin Disease Suzhou Suncadia Biopharmaceuticals Co Ltd 2019-05-29 Lymphoma; Breast Neoplasms; Respiratory Tract Neoplasms; Nasopharyngeal Carcinoma; Lymphoma, Extranodal NK-T-Cell; Sarcoma; Cholangiocarcinoma; Colorectal Neoplasms; Genital Neoplasms, Female; Urologic Neoplasms; Carcinoma, Squamous Cell; Endometrial Neoplasms; Urinary Bladder Neoplasms; Paranasal Sinus Neoplasms; Esophageal Squamous Cell Carcinoma; Uterine Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Melanoma; Gastrointestinal Neoplasms; Neoplasm Metastasis; Esophageal Diseases; Small Cell Lung Carcinoma; Carcinoma, Bronchogenic; Ovarian Neoplasms; Solid tumours; Hemorrhagic Fever, Ebola; Biliary Tract Neoplasms; Stomach Neoplasms; Rectal Neoplasms; Thoracic Neoplasms; Bronchial Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Liver Neoplasms; Nasopharyngeal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Hypopharyngeal Neoplasms; Hodgkin Disease; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neopl Details
Pembrolizumab SCH-900475; h409A11; MK-3475 Approved Merck & Co Inc 可瑞达, Keytruda United States Melanoma Merck Sharp & Dohme Corp 2014-09-04 Liver Neoplasms; Hematologic Neoplasms; Solid tumours; Lymphoma, B-Cell; Kidney Neoplasms; HIV Infections; Bone metastases; Ovarian Neoplasms; Head and Neck Neoplasms; Biliary Tract Neoplasms; Lymphoma, B-Cell, Marginal Zone; Intestinal Neoplasms; Leiomyosarcoma; Erythema; Lymphoma, T-Cell, Peripheral; Ovarian germ cell tumor; Neoplasm Recurrence, Local; Neoplasm, Residual; Thyroid Diseases; Medulloblastoma; Ependymoma; Colorectal Neoplasms, Hereditary Nonpolyposis; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Anus Neoplasms; Carcinoid Tumor; Mismatch Repair Deficient Cancer; Cystadenocarcinoma, Serous; Pheochromocytoma; Carcinoma; Vaginitis; Thoracic Neoplasms; Leukemia, Lymphoid; Rectal Neoplasms; Genital Neoplasms, Male; Polycythemia Vera; Vaginal Diseases; Spinal Cord Neoplasms; Carcinoma, Transitional Cell; Hodgkin Disease; Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Hypopharyngeal Neoplasms; T Details
Nivolumab MDX-1106; BMS-936558; BMS-936558-01; ono-0123; ONO-4538 Approved Ono Pharmaceutical Co Ltd, Bristol-Myers Squibb Company 欧狄沃, Opdivo Japan Melanoma Ono Pharmaceutical Co Ltd 2014-07-04 Liver Neoplasms; Hematologic Neoplasms; Solid tumours; Drug-Related Side Effects and Adverse Reactions; Head and Neck Neoplasms; Biliary Tract Neoplasms; Tobacco Smoking; Lymphoma, T-Cell, Peripheral; Acquired Immunodeficiency Syndrome; Bone Marrow Neoplasms; Kidney Neoplasms; HIV Infections; Leukemia, Myelogenous, Chronic; Hematopoietic stem cell transplantation (HSCT); Ependymoma; Medulloblastoma; Colorectal Neoplasms, Hereditary Nonpolyposis; Leiomyosarcoma; Ovarian Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Anus Neoplasms; Mismatch Repair Deficient Cancer; Leukemia, Lymphoid; Leukoplakia, Oral; Carcinoma; Carcinoma, Merkel Cell; Giant Cell Arteritis; Polycythemia Vera; Inflammatory Bowel Diseases; Dermatomyositis; Thoracic Neoplasms; Small Cell Lung Carcinoma; Nasopharyngeal Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Sepsis; Hodgkin Disease; Autoimmune Diseases; Myelodysplastic Syndromes; Coronavirus D Details
Sintilimab IBI-308 Approved Innovent Biologics(Suzhou) Co Ltd Tyvyt, 达伯舒 Mainland China Hodgkin Disease Innovent Biologics(Suzhou) Co Ltd 2018-12-24 Lung Diseases; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Lung Neoplasms; Endometrial Neoplasms; Neoplasms, Unknown Primary; Lymphoma, Non-Hodgkin; Esophageal Squamous Cell Carcinoma; Colorectal Neoplasms; Lymphoma, Extranodal NK-T-Cell; Sarcoma; Lymphoma, T-Cell, Peripheral; Respiratory Tract Diseases; Nasopharyngeal Neoplasms; Neoplasms; Hodgkin Disease; Thoracic Neoplasms; Hemangiosarcoma; Esophageal Neoplasms; Stomach Neoplasms; Solid tumours; Liver Neoplasms Details
Retifanlimab MGA-012; INCMGA-0012; INCMGA-00012 Approved Macrogenics Inc ZYNYZ United States Carcinoma, Merkel Cell Incyte Corp 2023-03-22 Carcinoma, Squamous Cell; Neuroendocrine Tumors; Liposarcoma; Breast Neoplasms; Lymphoma, Follicular; Sarcoma; Astrocytoma; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Glioma; Digestive System Neoplasms; Endometrial Neoplasms; Esophageal adenocarcinoma; Penile Neoplasms; Neoplasm Metastasis; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Melanoma; Neoplasms; Solid tumours; Ovarian Neoplasms; Lymphoma, B-Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Anus Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Merkel Cell; Head and Neck Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Malignant Carcinoid Syndrome; Lymphoma, Large B-Cell, Diffuse; Glioblastoma; Prostatic Neoplasms, Castration-Resistant; Oligodendroglioma; Urinary Bladder Neoplasms Details
Penpulimab AK-105 Approved Zhongshan Akeso Biopharma Co Ltd 安尼可, ANNIKO Mainland China Hodgkin Disease Zhengda Tianqing Kangfang (Shanghai) Biomedical Technology Co Ltd 2021-08-03 Neuroendocrine Tumors; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Urologic Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Microsatellite instability-high cancer; Neoplasms; Hodgkin Disease; Small Cell Lung Carcinoma; Esophageal Neoplasms; Thoracic Neoplasms; Liver Neoplasms; Head and Neck Neoplasms Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Budigalimab ABBV-181 Phase 3 Clinical Abbvie Inc HIV Infections; Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Cetrelimab JNJ-63723283; JNJ-3283 Phase 3 Clinical Johnson & Johnson Solid tumours; Hepatitis B, Chronic; Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Nofazinlimab CS-1003 Phase 3 Clinical Cstone Pharmaceuticals Solid tumours; Neoplasms; Lymphoma; Carcinoma, Hepatocellular Details
Sasanlimab RN-888; PF-06801591; PF-6801591 Phase 3 Clinical Pfizer Inc Endometrial Neoplasms; Lymphoma, Large B-Cell, Diffuse; Digestive System Neoplasms; Urinary Bladder Neoplasms; Urologic Diseases; Sarcoma; Prostatic Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Colorectal Neoplasms; Triple Negative Breast Neoplasms; Urogenital Neoplasms; Carcinoma, Squamous Cell; Gastrointestinal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Fructose Intolerance; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Kidney Neoplasms; Liver Neoplasms; Head and Neck Neoplasms; Lymphoma, T-Cell, Peripheral; Skin Melanoma; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Neoplasms; Neoplasms, Glandular and Epithelial; Kidney Diseases; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Hodgkin Disease Details
BAT-1308 BAT-1308 Phase 3 Clinical Bio-Thera Solutions Ltd Solid tumours; Triple Negative Breast Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms Details
Genolimzumab CBT-501; APL-501; APL501; GB226; GB-226 Phase 3 Clinical Cbt, Genor Biopharma Co Ltd, Apollomics Inc Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Lymphoma, Non-Hodgkin; Sarcoma, Alveolar Soft Part; Thymoma; Lymphoma; Neoplasms, Unknown Primary; Lymphoma, T-Cell, Peripheral; Thymus Neoplasms; Microsatellite Instability; Hodgkin Disease; Carcinoma, Renal Cell; Mismatch Repair Deficient Cancer; Lymphoma, B-Cell; Solid tumours Details
Volrustomig MEDI-5752; MEDI5752 Phase 3 Clinical Medimmune Llc Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma, Renal Cell; Mesothelioma; Sarcoma; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular Details
BCD-217 BCD-217 Phase 3 Clinical Biocad Melanoma Details
Tebotelimab PD-1 X LAG-3; MGD-013 Phase 3 Clinical Macrogenics Inc Triple Negative Breast Neoplasms; Adenocarcinoma; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Endometrial Neoplasms; Cholangiocarcinoma; Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Liver Neoplasms; Biliary Tract Neoplasms; Hematologic Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms Details
Rulonilimab F-520 Phase 3 Clinical Shandong New Time Pharmaceutical Co Ltd Lymphoma, T-Cell, Peripheral; Solid tumours; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Central Nervous System Lymphoma; Uterine Cervical Neoplasms Details
Pembrolizumab biosimilar (Amgen) ABP 234; ABP-234 Phase 3 Clinical Amgen Inc Carcinoma, Non-Small-Cell Lung Details
Pembrolizumab biosimilar (Laboratorio Elea Phoenix Sa) MB-12; MB12 Phase 3 Clinical Laboratorio Elea Phoenix Sa Carcinoma, Non-Small-Cell Lung Details
Pembrolizumab biosimilar(R-Pharm) RPH-075 Phase 3 Clinical R-Pharm Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung Details
Pembrolizumab Biosimilar (Samsung Bioepis ) SB27; SB-27 Phase 3 Clinical Samsung Bioepis Co Ltd Carcinoma, Non-Small-Cell Lung Details
GME-751 GME751; GME-751 Phase 3 Clinical Sandoz Melanoma; Carcinoma, Non-Small-Cell Lung Details
BAT-3306 BAT3306; BAT-3306 Phase 3 Clinical Bio-Thera Solutions Ltd Carcinoma, Non-Small-Cell Lung Details
PD-1 Inhibitor Therapy(Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University) Phase 3 Clinical Sun Yat-Sen Memorial Hospital Of Sun Yat-Sen University Rejection of liver transplantation; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Hepatocellular Details
Nivolumab biosimilar(Amgen) ABP-206 Phase 3 Clinical Amgen Inc Melanoma Details
Pembrolizumab biosimilar (biocad) BCD-201 Phase 3 Clinical Biocad Solid tumours; Melanoma; Carcinoma, Non-Small-Cell Lung Details
MK-3475A MK-3475A Phase 3 Clinical Merck Sharp & Dohme Corp Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Lung Neoplasms; Carcinoma, Squamous Cell; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Pembrolizumab/Vibostolimab MK-7684A Phase 3 Clinical Merck & Co Inc Urinary Bladder Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Gallbladder Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Cholangiocarcinoma; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Hematologic Neoplasms Details
Rilvegostomig AZD-2936 Phase 3 Clinical Astrazeneca Plc Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Pembrolizumab/Quavonlimab MK-1308A Phase 3 Clinical Merck Sharp & Dohme Corp, Msd Ireland (Carlow), MSD R&D（China）Co Ltd Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma Details
Mavezelimab/Pembrolizumab MK-4280A; MK-4820A Phase 3 Clinical Msd Ireland (Carlow) Merck Sharp & Dohme Corp, MSD R&D（China）Co Ltd Solid tumours; Carcinoma, Renal Cell; Hodgkin Disease; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Endometrial Neoplasms Details
Nivolumab biosimilar (Shandong Boan Biotechnology) LY-01015; BA-1104 Phase 3 Clinical Shandong Boan Biotechnology Co Ltd Liver Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Glioma; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Spartalizumab PDR-001 Phase 3 Clinical Novartis Pharma Ag Esophageal Squamous Cell Carcinoma; Chordoma; Digestive System Neoplasms; Neuroendocrine Tumors; Nasopharyngeal Carcinoma; Breast Neoplasms; Sarcoma; Prostatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Primary Myelofibrosis; Bone Marrow Diseases; Esophageal adenocarcinoma; Endometrial Neoplasms; Carcinoma, Squamous Cell; Microsatellite instability-high cancer; Carcinoma, Pancreatic Ductal; Lung Neoplasms; Lymphoma; Sarcoma, Alveolar Soft Part; Leukemia, Myeloid, Acute; Thyroid Neoplasms; Metastatic breast cancer; Uterine Neoplasms; Adenocarcinoma; Persistent Fetal Circulation Syndrome; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms; Lymphoma, Large B-Cell, Diffuse; Solid tumours; Ovarian Neoplasms; Liver Neoplasms; Leukemia, Myeloid; Leukemia; Kidney Neoplasms; Preleukemia; Hematologic Diseases; Carcinoma, Renal Cell; Carcinoma; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Anus Neoplasms; Triple Negati Details
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Lymphoma, B-Cell Details
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) ICTCAR-014 Phase 2 Clinical Innovative Cellular Therapeutics Co Ltd Lymphoma, Non-Hodgkin Details
Pimivalimab JTX-4014 Phase 2 Clinical Jounce Therapeutics Inc Neoplasms; Carcinoma, Non-Small-Cell Lung Details
MAX-10181 MAX-10181; MAX-1 Phase 2 Clinical Maxinovel Pharmaceuticals Co Ltd Solid tumours; Neoplasms Details
Tobemstomig RO-7247669 Phase 2 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Liver Neoplasms; Carcinoma; Carcinoma, Renal Cell; Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
SI-B003 SI-B003 Phase 2 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Breast Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma Details
Multiple target antigen stimulating cell therapy (HengRui YuanZheng Biotechnology) Phase 2 Clinical Hengrui Yuanzheng (Shanghai) Biotechnology Co Ltd Solid tumours; Liver Neoplasms; Stomach Neoplasms; Neoplasms; Liver Diseases Details
Vudalimab XmAb-20717; XmAb-717; XmAb 717 Phase 2 Clinical Xencor Inc Thymoma; Adenocarcinoma, Clear Cell; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Vulvar Neoplasms; Prostatic Neoplasms; Astrocytoma; Colorectal Neoplasms; Endometrial Neoplasms; Microsatellite instability-high cancer; Carcinoma, Neuroendocrine; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Ovarian Epithelial; Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Carcinoma, Basal Cell; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Hodgkin Disease; Adenoma, Acidophil; Colonic Neoplasms; Mesothelioma; Adnexal Diseases; Prostatic Neoplasms, Castration-Resistant Details
Recombinant humanized anti-PD-1 monoclonal antibody (Shanghai CP Guojian) 609-A; SSGJ-609A; SSGJ-609-A Phase 2 Clinical Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd Solid tumours; Sarcoma; Breast Neoplasms Details
Lorigerlimab MGD-019; AEX1344 Phase 2 Clinical Macrogenics Inc Solid tumours; Liver Neoplasms; Skin Melanoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung Details
PD-1 knockout EBV-CTL (Nanjing Medical University) Phase 2 Clinical Nanjing Medical University Stomach Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Neoplasms; Lymphoma Details
Izuralimab XmAb-23104; XmAb-104 Phase 2 Clinical Xencor Inc Sarcoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Endometrial Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms Details
Peresolimab LY-3462817 Phase 2 Clinical Eli Lilly And Company Arthritis, Rheumatoid; Autoimmune Diseases; Connective Tissue Diseases; Immune System Diseases; Joint Diseases; Psoriasis; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis Details
Lomvastomig RG-7769; RO-7121661 Phase 2 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Neoplasms; Small Cell Lung Carcinoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma Details
MiHA-loaded PD-L silenced DC vaccination (Radboud University) Phase 2 Clinical Radboud University Nijmegen Hematologic Neoplasms; Colorectal Neoplasms Details
ZG-005 ZG-005 Phase 2 Clinical Gensun Biopharma Inc Solid tumours; Neoplasms; Carcinoma, Neuroendocrine; Uterine Cervical Neoplasms Details
T-3011 T-3 (ImmVira Pharma); MVR-T3011; T3011; MVR-T3011 IT; MVR-T3011 IV; B015; B-015 Phase 2 Clinical Immvira Co Ltd Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Squamous Cell; Lymphoma; Endometrial Neoplasms; Lung Neoplasms; Colorectal Neoplasms; Sarcoma; Liver Neoplasms; Ascites; Mesothelioma; Small Cell Lung Carcinoma; Skin Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms Details
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) Phase 2 Clinical Shanghai Cell Therapy Research Institute Neoplasms Details
TY-101 TY-101; TY101 Phase 2 Clinical Tayu Huaxia Biotech Medical Group Co Ltd Solid tumours; Lymphoma Details
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) Phase 2 Clinical People'S Liberation Army General Hospital Military Service Multiple Myeloma Details
Sabestomig AZD-7789 Phase 2 Clinical AstraZeneca Ag Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Hodgkin Disease; Digestive System Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms Details
TC-510 TC-510 Phase 2 Clinical Tcr2 Therapeutics Inc Ovarian Neoplasms; Solid tumours; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Mesothelioma; Cholangiocarcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma Details
Anti-PD-1 Antibody(Jiangxi Provincial Cancer Hospital) Phase 2 Clinical Jiangxi Provincial Cancer Hospital Nasopharyngeal Carcinoma Details
Ezabenlimab BI-754091 Phase 2 Clinical C.H. Boehringer Sohn Ag & Co. Kg Sarcoma; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Head and Neck Neoplasms; Colonic Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Liver Neoplasms; Biliary Tract Neoplasms; Solid tumours Details
PD-1 Inhibitor Therapy(Affiliated Hospital of Nantong University) Phase 2 Clinical Affiliated Hospital Of Nantong University Esophageal Squamous Cell Carcinoma Details
PD-1 inhibitor therapy(Shanghai Chest Hospital) Phase 2 Clinical Shanghai Chest Hospital Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma Details
Recombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology) Phase 2 Clinical Anhui Anke Biotechnology (Group) Co Ltd Esophageal Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Neoplasms; Lymphoma; Lung Neoplasms Details
PD-1 Monoclonal Antibody(Sixth Affiliated Hospital Sun Yat-Sen University) Phase 2 Clinical Sixth Affiliated Hospital Sun Yat-Sen University Neoplasms; Colorectal Neoplasms Details
PD-1 Inhibitor Therapy(Beijing YouAn Hospital) Phase 2 Clinical Beijing Youan Hospbeijing Youan Hospital,Capital Medical Universityital,Capital Medical University, Beijing Gene Key Life Technology Co Ltd Carcinoma, Hepatocellular Details
Autologous PD-1 antibody expressing mesothelin-targeted CAR-Tcells therapy (Shanghai Cell Therapy Research Institute) Phase 2 Clinical Shanghai Cell Therapy Research Institute Solid tumours Details
SAR-445877 SAR445877; SAR-445877; KD050; KD-050 Phase 2 Clinical Sanofi, Kadmon Corporation Llc Solid tumours Details
Peramprizumab Phase 2 Clinical Sun Yat-Sen University Nasopharyngeal Carcinoma Details
IBI-363 IBI-363 Phase 2 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms; Lymphoma; Melanoma Details
EBV-specific TCR-T cell with anti-PD1 auto-secreted element Phase 2 Clinical Tcrcure Biopharma Ltd Squamous Cell Carcinoma of Head and Neck Details
Anti-CTLA-4/PD-1 expressing EGFR-CAR-T Phase 2 Clinical Shanghai Cell Therapy Research Institute Solid tumours Details
HerinCAR-PD1 Phase 2 Clinical Ningbo Cancer Hospital Solid tumours Details
IAP-0971 IAP-0971 Phase 2 Clinical SunHo (China) BioPharmaceutical Co Ltd Solid tumours; Neoplasms; Urinary Bladder Neoplasms Details
Rosnilimab ANB-030 Phase 2 Clinical Anaptysbio Inc Alopecia Areata; Arthritis, Rheumatoid; Colitis, Ulcerative Details
TQB-2868 TQB-2868 Phase 2 Clinical Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group Neoplasms; Pancreatic Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms Details
Pidilizumab MDV-9300; CT-011 Phase 2 Clinical Curetech Ltd Ovarian Neoplasms; Carcinoma, Renal Cell; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Colonic Neoplasms; Multiple Myeloma; Prostatic Neoplasms; Breast Neoplasms; Sarcoma; Colorectal Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Hepatitis C, Chronic; Melanoma; Carcinoma, Hepatocellular Details
Pradusinstobart LVGN-3616; SSI-361 Phase 2 Clinical Lyvgen Biopharma(HK)Ltd Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Papillomavirus Infections; Uveal melanoma; Sarcoma; Carcinoma, Hepatocellular; Neoplasm Metastasis Details
LBL-015 LBL-015 Phase 2 Clinical Nanjing Leads Biolabs Co Ltd Solid tumours Details
EMB-02 EMB-02 Phase 2 Clinical Shanghai Epimab Biotherapeutics, Inc Solid tumours Details
Acrixolimab YBL-006; YBL 006 Phase 2 Clinical Y-biologics Inc Solid tumours Details
PD-1 knockout engineered T cells (Anhui Kedgene Biotechnology) Phase 2 Clinical Anhui Korton Biological Technology Co Ltd, Hangzhou Cancer Hospital Esophageal Neoplasms; Carcinoma, Hepatocellular Details
Lipustobart LZM-009 Phase 2 Clinical Livzon(Group) Pharmaceutical Factory Solid tumours; Thymoma; Carcinoma, Non-Small-Cell Lung Details
PD-1 knockout engineered T cells (Chengdu MedGenCell) Phase 2 Clinical West China Hospital Of Sichuan University, Chengdu Medgencell Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma Details
HX-009 HX-009 Phase 2 Clinical Hanx Biopharmaceutical Co Ltd, Wuhan Hanxiong Biotechnology Co Ltd Solid tumours; Liver Neoplasms; Stomach Neoplasms; Lymphoma Details
MEDI-0680 AMP-514; MEDI-0680 Phase 2 Clinical Medimmune Lymphoma, B-Cell; Kidney Neoplasms; Carcinoma, Renal Cell; Neoplasms Details
PE0105 PE-0105 Phase 1 Clinical Shanghai Yunyi Health Technology Development Co Ltd Solid tumours; Neoplasms Details
Recombinant human PD-1 antibody herpes simplex virus Phase 1 Clinical Yangsheng Tang Co Ltd, Xiamen University Liver Neoplasms; Solid tumours; Head and Neck Neoplasms; Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Colorectal Neoplasms; Brain metastases; Lung Neoplasms; Melanoma; Uterine Cervical Neoplasms Details
GX-P1 GX-P1 Phase 1 Clinical Genexine Inc Autoimmune Diseases Details
Fidasimtamab IBI-315 Phase 1 Clinical Hanmi Pharmaceutical Co Ltd, Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms Details
Zeluvalimab AMG-404 Phase 1 Clinical Amgen Inc Solid tumours; Small Cell Lung Carcinoma; Prostatic Neoplasms, Castration-Resistant; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CC-90006 C-90006; CC-90006 Phase 1 Clinical Anaptysbio Inc Autoimmune Diseases; Psoriasis Details
RO-7284755 RO-7284755 Phase 1 Clinical F. Hoffmann-La Roche Ag Solid tumours; Neoplasms Details
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) LXF-821 Phase 1 Clinical University Of Pennsylvania, Novartis Pharma Ag Glioblastoma Details
Sym-021 Sym-021; S-95016; Sym021 Phase 1 Clinical Symphogen A/S Solid tumours; Lymphoma; Neoplasm Metastasis Details
ONO-4685 ONO-4685 Phase 1 Clinical Merus Nv Psoriasis; Lymphoma, T-Cell; Plaque psoriasis Details
RB-0004 RB-0004 Phase 1 Clinical Reyoung Pharmaceutical Co Ltd Solid tumours; Lymphoma Details
CMAB-819 CMAB8-19 Phase 1 Clinical Sinomab Bioscience Ltd Squamous Cell Carcinoma of Head and Neck; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Taminadenant NIR-178; PBF-509 Phase 1 Clinical Palobiofarma Sl Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Carcinoma, Renal Cell; Carcinoma; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Colorectal Neoplasms; Parkinson Disease; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma Details
JS-207 JS-207 Phase 1 Clinical Shanghai Junshi Biological Engineering Co Ltd Neoplasms Details
Mableukin 2PD1 (Anwita Biosciences) AWT020; AWT-020 Phase 1 Clinical Anwita Biosciences Inc Neoplasms; Autoimmune Diseases of the Nervous System Details
ASKG-915 ASKG-915 Phase 1 Clinical Askgene Pharma Solid tumours; Neoplasms Details
707（3SBio） Phase 1 Clinical 3sbio Inc Solid tumours Details
CTX-8371 CTX-8371 Phase 1 Clinical Compass Therapeutics LLC Solid tumours; Squamous Cell Carcinoma of Head and Neck; Hodgkin Disease; Triple Negative Breast Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Reozalimab IBI-318; LY-3434172; LY3434172 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd, Eli Lilly And Company Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular Details
Toripalimab (Shanghai Junshi Biosciences) JS001sc (Shanghai Junshi Biosciences) Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Neoplasms Details
BZT-2312 BZT-2312; Fast CAR T cells Phase 1 Clinical Shanghai Cell Therapy Group Co Ltd Solid tumours Details
BZE-2209 BZE-2209; BZE2209; αPD1/CTLA4-MSLN-CAR T Cells Phase 1 Clinical Shanghai Cell Therapy Group Co Ltd Solid tumours Details
BCD-263 BCD-263 Phase 1 Clinical Biocad Melanoma Details
QL-2107 QL2107; QL-2107 Phase 1 Clinical Qilu Pharmaceutical Co Ltd Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
STW204/Gotistobart AI-061 Phase 1 Clinical Oncoc4 Inc Colorectal Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fallopian Tube Neoplasms; Bile Duct Neoplasms; Carcinoma, Renal Cell; Peritoneal Neoplasms; Digestive System Neoplasms; Urinary Bladder Neoplasms; Stomach Neoplasms; Anus Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Cystadenocarcinoma, Serous Details
INCA33890 INCA33890; INCA-33890 Phase 1 Clinical Incyte Corp Solid tumours; Neoplasms; Neoplasm Metastasis Details
INCA-32459 INCA-32459 Phase 1 Clinical Incyte Corp, Merus Nv Neoplasms Details
JNJ-67484703 JNJ-67484703; JNJ-4703 Phase 1 Clinical Janssen Research & Development Llc Arthritis, Rheumatoid Details
KY-0118 KY-0118; KY0118 Phase 1 Clinical Novatim Immune Therapeutics (Zhejiang) Co Ltd Solid tumours; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Sym-024 Sym-024; S-95024 Phase 1 Clinical Symphogen A/S Solid tumours; Neoplasm Metastasis Details
SOT-201 SOT-201 Phase 1 Clinical Sotio Solid tumours; Neoplasms; Neoplasm Metastasis Details
Pegylated recombinant human granulocyte colony stimulating factor(Sun Yat-sen University) Phase 1 Clinical Sun Yat-Sen University Hematologic Neoplasms; Nasopharyngeal Carcinoma Details
ABBV-1882 ABBV-1882 Phase 1 Clinical Abbvie Inc HIV Infections Details
CDX-585 CDX-585 Phase 1 Clinical Boaoxin Biotechnology(Nanjing) Co Ltd, Celldex Therapeutics Liver Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung Details
AK-129 AK-129 Phase 1 Clinical Zhongshan Akeso Biopharma Co Ltd Neoplasms; Hodgkin Disease Details
AK-131 AK-131 Phase 1 Clinical Zhongshan Akeso Biopharma Co Ltd Solid tumours; Neoplasms Details
89Zr-N-sucDf-pembrolizumab Phase 1 Clinical Merck & Co Inc, Umcg The University Medical Center Groningen Melanoma; Carcinoma, Non-Small-Cell Lung Details
706-3SBio SSGJ-706; 706 anti -PD1/PD -L1 BsAb; 706 anti-PD1/PD-L1 Bispecific antibody Phase 1 Clinical 3sbio Inc Solid tumours; Composite Lymphoma; Lymphoma Details
Latikafusp AMG-256 Phase 1 Clinical Amgen Inc Solid tumours Details
Recombinant human anti-PD-1 monoclonal antibody(Hec Biological) Phase 1 Clinical Dongguan City Hec Biological Medicine Res And Development Co Ltd Stomach Neoplasms; Esophageal adenocarcinoma Details
RG-6279 RG-6279 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours Details
CA-170 CA-170; AUPM-170 Phase 1 Clinical Aurigene Solid tumours Details
SHR-1901 SHR-1901 Phase 1 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd Neoplasms Details
SSGJ-705 705; SSGJ-705 Phase 1 Clinical Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd Solid tumours; Neoplasms Details
Anti-PD1/anti-TIM3 bispecific antibody (L&L vision biopharmaceuticals) Bis-5 Phase 1 Clinical L&L Biopharma Co Ltd Solid tumours; Neoplasms Details
CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) Phase 1 Clinical Second Affiliated Hospital Of Zhejiang University School Of Medicine Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Primary mediastinal B cell lymphoma Details
IBI-321 IBI-321 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms Details
PH-762 PH-762; PH762-ACT; RXI 762-ACT Phase 1 Clinical Phio Pharmaceuticals Corp Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Skin Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Genital Neoplasms, Female; Colorectal Neoplasms; Carcinoma, Squamous Cell; Urogenital Neoplasms; Lung Neoplasms; Melanoma Details
JS-201 JS-201 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Neoplasms Details
IMU-201 IMU-201 Phase 1 Clinical Imugene Ltd Adenocarcinoma of Lung; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
CD-200-AR-L CD-200-AR-L; hP-1-A-8 Phase 1 Clinical University Of Minnesota, OX2 Therapeutics Glioblastoma; Glioma Details
PF-07209960 PF-07209960 Phase 1 Clinical Pfizer Inc Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
GNR-051 GNR-051 Phase 1 Clinical Generium Pharmaceuticals Carcinoma, Renal Cell; Melanoma; Carcinoma, Non-Small-Cell Lung Details
IBI-319 IBI-319 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Neoplasms Details
NWY-001(Biocytogen Pharmaceuticals) NWY001(Biocytogen Pharmaceuticals); YH008; YH-008; NWY-001(Biocytogen Pharmaceuticals) Phase 1 Clinical Eucure Pharmaceutical Technology (Beijing) Co Ltd, Biocytogen Pharmaceuticals (Beijing) Co Ltd Solid tumours; Hematologic Neoplasms; Neoplasms Details
VT1093 VT1093; VT-1093 Phase 1 Clinical Beijing Weiyuan Likang Biotechnology Co Ltd Solid tumours Details
αPD1-MSLN-CAR T cell therapy (Shanghai Cell Therapy Group Co.,Ltd) BZDS1901; BZDS-1901; BZD1901 Phase 1 Clinical Shanghai Cell Therapy Group Co Ltd Ovarian Neoplasms; Solid tumours; Mesothelioma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Recombinant humanized anti-PD-1 monoclonal antibody (Shanxi Wichida Bright Pharmaceutical) Phase 1 Clinical Shanxi Weiqidaguangming Pharmaceutical Co Ltd Solid tumours Details
MW-11 MW-11; 9MW1111; 9-MW1111; 9MW-1111; 9-MW-1111 Phase 1 Clinical Mabwell (Shanghai) Bioscience Co Ltd Solid tumours; Breast Neoplasms Details
STW204 STW-204; AI025; AI-025 Phase 1 Clinical Suzhou Stainwei Biotech Inc Solid tumours; Neoplasms Details
Rituximab/Paclitaxel AR-160 Phase 1 Clinical Mayo Clinic Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
64Cu-DOTA-nivolumab (Bristol-Myers Squibb/Ono Pharmaceutical) Clinical Ono Pharmaceutical Co Ltd, Bristol-Myers Squibb Company Melanoma; Carcinoma, Non-Small-Cell Lung Details
INSIX RA (Indus Biotech) Clinical Indus Biotech Pvt Ltd Arthritis, Rheumatoid; Inflammation Details
Treprilimab Clinical Sun Yat-Sen University Oropharyngeal Neoplasms Details
Anti-PD-1 Antibody(Fujian Cancer Hospital) Fujian Cancer Hospital Details
PD-1 Inhibitor Therapy(Hunan Cancer Hospital) Hunan Cancer Hospital Details

This web search service is supported by Google Inc.

totopphone
Call us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
日本：+(0)81-50-547-99099
Email
メールアドレス
order.jp@acrobiosystems.com
Fax
ファックス
+1 888-377-6111
Address
株式会社アクロバイオシステムズ
〒157-0066
東京都世田谷区成城1丁目26番9-101号

アクロバイオシステムズの公式アカウント

linkedin twitter facebook youtube

お問い合わせ（半角英文字で入力してください）

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap